Trial · NCT03711162
Outcomes35
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 35
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Annual Rate of Decline in FVC up to Week 52 | Baseline up to week 52 | Full Analysis Set - Efficacy (FAS-EF) included all randomized participants who received at least 1 dose of investigational product and excluded participants from the site found to have serious good clinical practice (GCP)-noncompliance issues. | mL/year | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants With Disease Progression up to Week 52 | Up to week 52 | Full Analysis Set- Efficacy | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Respiratory-Related Hospitalization Until End of Study (EoS) | Up to EoS (week 121) | Full Analysis Set- Efficacy | Percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in St.George's Respiratory Questionnaire (SGRQ) Total Score at Week 52 | Baseline, week 52 | Full Analysis Set- Efficacy | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Annual Rate of Decline in FVC Until EoS | Baseline up to EoS (week 121) | Full Analysis Set - Efficacy | mL/year | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants With Disease Progression Until EoS | Up to EoS (week 121) | Full Analysis Set - Efficacy | Percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in St.George's Respiratory Questionnaire (SGRQ) Total Score at Week 100 | Baseline, week 100 | Full Analysis Set - Efficacy | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants With All Cause Hospitalization Until EoS | Up to EoS (week 121) | Full Analysis Set - Efficacy | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Respiratory Related Mortality Until EoS | Up to EoS (week 121) | Full Analysis Set - Efficacy | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Hospitalized for Non-elective Lung Transplant Until EoS | Up to EoS (week 121) | Full Analysis Set - Efficacy | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation Until EoS | Up to EoS (week 121) | Full Analysis Set - Efficacy | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With All Cause Mortality or Hospitalization for Non-elective Lung Transplant Until EoS | Up to EoS (week 121) | FAS - EF with available data at specified time point. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With All Cause Mortality, Hospitalization for Non-elective Lung Transplant or Hospitalization for Qualifying for Lung Transplant Until EoS | Up to EoS (week 121) | Full Analysis Set - Efficacy | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With All-Cause Mortality or Hospitalization That Meets >=10% Absolute Decline in %FVC or Respiratory-Related Hospitalization Until EoS | Up to EoS (week 121) | Full Analysis Set - Efficacy | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With All-Cause Mortality or Respiratory-Related Hospitalizations Until EoS | Up to EoS (week 121) | Full Analysis Set - Efficacy | Percentage of participants | NUMBER |
| SECONDARY | FVC at Week 52 | Week 52 | FAS-EF with available data at specified time point. | mL | MEAN |
| SECONDARY | Change From Baseline in FVC at Week 52 | Baseline, week 52 | FAS-EF with available data at specified time point. | mL | MEAN |
| SECONDARY | Percent Change From Baseline in FVC at Week 52 | Baseline, week 52 | FAS-EF with available data at specified time point. | Percent change | MEAN |
| SECONDARY | FVC at Week 112 | Week 112 | FAS-EF with available data at specified time point. No participant was available for analysis at Week 112 for arm GLPG1690 200 mg and Placebo. | mL | MEAN |
| SECONDARY | Change From Baseline in FVC at Week 112 | Baseline, week 112 | FAS - EF with available data at specified time point. No participant was available for analysis at Week 112 for arms GLPG1690 200 mg and Placebo. | mL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03711162/outcomes